319 related articles for article (PubMed ID: 19821273)
1. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Sudlow CL; Mason G; Maurice JB; Wedderburn CJ; Hankey GJ
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD001246. PubMed ID: 19821273
[TBL] [Abstract][Full Text] [Related]
2. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Hankey GJ; Sudlow CL; Dunbabin DW
Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
[TBL] [Abstract][Full Text] [Related]
3. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Hankey GJ; Sudlow CL; Dunbabin DW
Stroke; 2000 Jul; 31(7):1779-84. PubMed ID: 10884487
[TBL] [Abstract][Full Text] [Related]
4. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
5. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976
[TBL] [Abstract][Full Text] [Related]
6. Triflusal for preventing serious vascular events in people at high risk.
Costa J; Ferro JM; Matias-Guiu J; Alvarez-Sabin J; Torres F
Cochrane Database Syst Rev; 2005 Jul; (3):CD004296. PubMed ID: 16034926
[TBL] [Abstract][Full Text] [Related]
7. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
Valentine N; Van de Laar FA; van Driel ML
Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
[TBL] [Abstract][Full Text] [Related]
8. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
CAPRIE Steering Committee
Lancet; 1996 Nov; 348(9038):1329-39. PubMed ID: 8918275
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Keller TT; Squizzato A; Middeldorp S
Cochrane Database Syst Rev; 2007 Jul; (3):CD005158. PubMed ID: 17636787
[TBL] [Abstract][Full Text] [Related]
10. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration
BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
[TBL] [Abstract][Full Text] [Related]
11. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
12. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Kamal AK; Naqvi I; Husain MR; Khealani BA
Cochrane Database Syst Rev; 2011 Jan; 2011(1):CD008076. PubMed ID: 21249700
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet agents for intermittent claudication.
Wong PF; Chong LY; Mikhailidis DP; Robless P; Stansby G
Cochrane Database Syst Rev; 2011 Nov; (11):CD001272. PubMed ID: 22071801
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease.
Squizzato A; Keller T; Romualdi E; Middeldorp S
Cochrane Database Syst Rev; 2011 Jan; (1):CD005158. PubMed ID: 21249668
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet agents and anticoagulants for hypertension.
Lip GY; Felmeden DC; Dwivedi G
Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003186. PubMed ID: 22161375
[TBL] [Abstract][Full Text] [Related]
18. Evidence with antiplatelet therapy and ADP-receptor antagonists.
Easton JD
Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
[TBL] [Abstract][Full Text] [Related]
19. The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Rogowski W; Burch J; Palmer S; Craigs C; Golder S; Woolacott N
Health Technol Assess; 2009 Jun; 13(31):iii-iv, ix-xi, 1-77. PubMed ID: 19573471
[TBL] [Abstract][Full Text] [Related]
20. The thienopyridines in coronary artery disease.
Berger PB
Curr Cardiol Rep; 1999 Sep; 1(3):192-8. PubMed ID: 10980841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
